Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of BI 3031185 in Healthy Japanese Participants
NCT07656792Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3031185 (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Treatment-Emergent Adverse Events at 47 days, Area under the concentration-time curve from zero to infinity at 29 days and 1 more. Started Jul 2026; status: terminated.
02
Drugs
BI 3031185
Beyond the preview
Go deeper on NCT07656792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656792.